Journal Watch · Clinical Pharmacology & Therapeutics · 2026

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients.

Finally, we demonstrate the validation of the QSP model and approach by comparing its predictions with evolving preliminary safety, PK, and antimyeloma activity data from the ongoing TRIgnite-1 clinical trial.

Chandralayam Ayyappa Menon V, Matsuura T, Holkova B et al.Clinical Pharmacology & Therapeutics3 min readPharma relevance 75/100

DOI: 10.1002/cpt.70319PMID: 42206665Study type: cohort / observational clinical study

TL;DR

Finally, we demonstrate the validation of the QSP model and approach by comparing its predictions with evolving preliminary safety, PK, and antimyeloma activity data from the ongoing TRIgnite-1 clinical trial.

Key findings

  • We used a novel quantitative systems pharmacology (QSP) model to inform FIH dose selection and predict the clinical efficacy dose range for ISB 2001.
  • This modeling strategy enabled an efficient dose escalation design for the TRIgnite-1.
  • This approach is consistent with the emerging FDA roadmap to reduce animal testing by utilizing computational modeling methodologies for FIH dose selection.
  • Finally, we demonstrate the validation of the QSP model and approach by comparing its predictions with evolving preliminary safety, PK, and antimyeloma activity data from the ongoing TRIgnite-1 clinical trial.

What they did

Therefore, no pharmacokinetic, efficacy, or toxicology data could be generated in a fully cross-reactive preclinical species to facilitate prediction of optimal FIH dose or the clinical efficacy dose range. For T cell engagers (TCEs), the minimum anticipated biological effect level (MABEL) approach is widely used to derive FIH doses. While this method is considered safe, this standard approach may result in starting doses that are sometimes too low to elicit meaningful clinical activity, potentially leading to several dose escalation cohorts at subtherapeutic levels in seriously ill patients.

Full abstract (original)

Background: ISB 2001 is a trispecific antibody that binds to two tumor-associated antigens (TAA), CD38 and BCMA, and crosslinks to CD3 on T cells resulting in T cell-mediated cytotoxicity of tumor cells expressing these TAAs. ISB 2001 is currently being tested in relapsed and/or refractory multiple myeloma (RRMM) patients in the first-in-human (FIH) TRIgnite-1 study (NCT05862012). The CD3ε-binding domain of ISB 2001 does not cross-react with CD3 in cynomolgus monkeys.

What they did: Therefore, no pharmacokinetic, efficacy, or toxicology data could be generated in a fully cross-reactive preclinical species to facilitate prediction of optimal FIH dose or the clinical efficacy dose range. For T cell engagers (TCEs), the minimum anticipated biological effect level (MABEL) approach is widely used to derive FIH doses. While this method is considered safe, this standard approach may result in starting doses that are sometimes too low to elicit meaningful clinical activity, potentially leading to several dose escalation cohorts at subtherapeutic levels in seriously ill patients.

Results & conclusions: We used a novel quantitative systems pharmacology (QSP) model to inform FIH dose selection and predict the clinical efficacy dose range for ISB 2001. This modeling strategy enabled an efficient dose escalation design for the TRIgnite-1. This approach is consistent with the emerging FDA roadmap to reduce animal testing by utilizing computational modeling methodologies for FIH dose selection. Finally, we demonstrate the validation of the QSP model and approach by comparing its predictions with evolving preliminary safety, PK, and antimyeloma activity data from the ongoing TRIgnite-1 clinical trial.

Abstract © the authors / Clinical Pharmacology & Therapeutics (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1002/cpt.70319 · PubMed 42206665.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Clinical Pharmacology & Therapeutics for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Clinical Pharmacology & Therapeutics study find?

Finally, we demonstrate the validation of the QSP model and approach by comparing its predictions with evolving preliminary safety, PK, and antimyeloma activity data from the ongoing TRIgnite-1 clinical trial.

What type of study is this?

It is a cohort / observational clinical study, published in Clinical Pharmacology & Therapeutics in 2026. Therefore, no pharmacokinetic, efficacy, or toxicology data could be generated in a fully cross-reactive preclinical species to facilitate prediction of optimal FIH dose or the clinical efficacy dose range.

Where can I read the original paper?

The original is at the publisher via DOI 10.1002/cpt.70319. PubMed ID: 42206665. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Chandralayam Ayyappa Menon V, Matsuura T, Holkova B et al.. Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients.. Clinical Pharmacology & Therapeutics (2026). DOI: 10.1002/cpt.70319.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/clinical-validation-of-a-qsp-model-for-isb-2001-a-trispecific-t-cell-eng-t70319/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides